FemTech Startups Acquired by Major Health Systems

Major health systems are buying femtech companies for a reason that has nothing to do with chasing a trend⟦c2⟧. The acquisitions underway now are a response to a documented shortfall in how women's care has been funded, studied, and delivered for decades, and the specific capabilities changing hands show what these systems think care for women should look like going forward⟦c2⟧.

Women's health drew less research money, fewer clinical trials, and a thinner layer of supporting infrastructure than the population it serves would justify, for as long as anyone in the industry can point back. Femtech companies didn't invent a market out of nothing. They walked into rooms that were already empty: menopause care, fertility support, maternal mental health, pelvic floor conditions, chronic reproductive illness, all areas where the traditional system had built little and reached fewer patients than it should have.

That gap has stopped being an abstract equity concern and turned into a line item on a strategy memo. When a health system can't meet a patient where her actual condition is, whether that's perimenopause symptoms nobody diagnosed or a fertility question nobody answered well, she goes somewhere else. Direct-to-consumer platforms pick her up instead, and the system loses not just one visit but the whole chain of care that would have followed it: referrals, follow-ups, the lifetime revenue that comes from being someone's trusted provider. That's the loyalty erosion driving the acquisitions covered here.

The dollar figures make the case plainly. Investor-backed women's health companies produced more than $100 billion in acquisitions and IPOs between 2000 and 2025⟦c3⟧. That's not a number that describes a niche or a cause. It describes an asset class, and health system strategists read it that way. Buying a femtech company is now an admission, implicit but unmistakable, that the legacy women's health program wasn't built to handle what patients actually needed⟦c2⟧.

Femtech market growth before health systems moved

Figures on the femtech market swing wildly depending on who's counting and what they're counting, and that variance itself tells you something about how young this category still is. The broadest read, from Research and Markets, puts the market at $46.47 billion in 2025, climbing to $55.88 billion in 2026 at a 20.2% compound annual growth rate, with a forecast of $118.99 billion by 2030⟦c4⟧. A narrower definition limited to devices and software, from Mordor Intelligence, is $8.56 billion in 2025 and $9.78 billion in 2026⟦c5⟧. Neither number is wrong. They're measuring different things, one treating femtech as a sprawling category that touches telehealth, benefits administration and therapeutics, the other counting only the hardware and code⟦c5⟧.

Inside the U.S. Specifically, Straits Research values the market at $19.31 billion in 2025, rising to $22.42 billion in 2026, and Fortune Business Insights puts North America's share of the global market at 54.40% in 2025⟦c6⟧. It's local, it's well-capitalized, and it's coming from companies that raised money specifically to outcompete slow-moving incumbents⟦c8⟧.

PwC tracked nearly $60 billion flowing into core women's health segments between 2020 and 2025 across private equity, venture capital, and corporate money⟦c7⟧. That scale of capital is what turned femtech from a collection of scrappy startups into something with real acquisition targets: since 2010, the sector has produced 67 tracked acquisitions worth $3.8 billion in disclosed value and minted 13 unicorns⟦c9⟧. A sector needs a certain density of mature, well-run companies before acquisitions start making sense, and femtech crossed that threshold sometime in the last few years.

A wrinkle emerges here. Deloitte and SVB data show venture funding into women's health fell sharply in 2025⟦c10⟧. That sounds like bad news for the category, and in one sense it is. But a funding drought tends to make founders more willing to sell, not less, because runway gets shorter and the next round gets harder to close⟦c10⟧. If anything, the slowdown in venture dollars sets up more acquisition activity over the next two years, not less ⟦c61⟧.

What the confirmed acquisition deals reveal about buyer intent

Most of the confirmed exits in femtech are pharma companies, consumer telehealth platforms, and femtech firms buying other femtech firms rather than hospital systems buying startups. They're pharma companies, consumer telehealth platforms, and femtech firms buying other femtech firms. That pattern is itself the finding.

Take the largest deal on record. On February 19, 2026, Hims & Hers announced a definitive agreement to acquire Eucalyptus, and the deal closed in June 2026 at a total value of $1.15 billion⟦c11⟧⟦c12⟧. Eucalyptus runs five separate digital clinics, Juniper for women's weight loss, Kin for reproductive healthcare, Pilot and Compound for men's health, and Software for dermatology, so the women's health piece is one slice of a much larger business⟦c13⟧. The structure was $240 million in cash at closing, with the rest paid out as deferred and performance-based earnouts stretching to early 2029, against a customer base of roughly 775,000 people⟦c14⟧. Hims & Hers is a consumer telehealth company, not a hospital system, and that's exactly the point ⟦c11⟧. The buyer with the deepest pockets for femtech capability at scale wasn't a hospital at all⟦c15⟧.

Pharma got there earlier. Bayer bought KaNDy Therapeutics in 2020 for $425 million upfront, with milestone payments that could push the total to $875 million, for a non-hormonal menopause treatment still in KaNDy's pipeline⟦c16⟧⟦c17⟧. Bayer wasn't buying market share. The HoneyPot Company sold for $380 million in 2024, and the buyer's identity isn't confirmed in available records⟦c19⟧⟦c20⟧.

Most of the rest of the confirmed activity is femtech buying femtech. Progyny closed its acquisition of Apryl GmbH, a Berlin-based fertility benefits platform, on June 17, 2024, for €5.1 million ($5.3 million) net of cash⟦c21⟧⟦c22⟧. That's a tuck-in, plain and simple: Progyny wasn't acquiring a new capability, it was buying a foothold in Europe⟦c23⟧. Neither of those deals involved a health system as buyer or seller. They're consolidation inside the category itself⟦c26⟧.

Two more deals round out the picture ⟦c61⟧. Iron Health, a virtual care company covering primary care, behavioral health, weight management, and pregnancy care, was acquired by Metronomic in December 2024 on undisclosed terms⟦c27⟧⟦c28⟧. The breadth of what Iron Health offered under one roof, several distinct care moments bundled into a single platform, is exactly the "full stack" structure that acquirers keep gravitating toward⟦c29⟧. And LifeMD picked up Optimal Human Health MD in 2025 specifically to add women's health services to its existing business, rather than build that capability from scratch⟦c30⟧⟦c31⟧. Line these deals up and a pattern holds: acquirers are clustering around telehealth infrastructure, reproductive health, menopause therapeutics, and fertility benefits administration, not general wellness apps. They're buying clinical capability, and they're paying for it accordingly. Maven Clinic acquired Naytal in March 2023 for an undisclosed sum ⟦c24⟧. Maven acquired Naytal, a UK-based femtech provider, to integrate personalized fertility and pregnancy planning programs and expand into UK/European markets; Research and Markets reports the deal ⟦c25⟧.

The partnership-before-acquisition model: how Diana Health embeds inside HCA

Acquisition isn't the only door health systems are walking through, and it may not even be the main one. A quieter model has taken hold where a health system embeds a femtech operator inside its own facilities, lets it run, and watches how it performs before ever discussing a purchase price.

Diana Health is the clearest documented case of this ⟦c1⟧. It runs women's health programs built on the midwifery model of care, physically embedded inside partner hospitals, including HCA TriStar StoneCrest Medical Center and HCA TriStar NorthCrest Medical Center, both HCA facilities, along with Cookeville Regional Medical Center, which is not part of HCA⟦c32⟧⟦c33⟧. The company raised $55 million in a Series C round led by HealthQuest Capital in September 2025, bringing its total fundraising to $101 million⟦c34⟧. For a health system sizing up femtech targets, that's a far cheaper way to test a model than writing an acquisition check up front, and for a startup like Diana Health, it means real revenue and a credible reference client, at the cost of some independence⟦c35⟧.

Hinge Health took a related but distinct path ⟦c1⟧. In 2024 it began building out menopause and perimenopause support by partnering with Midi Health rather than acquiring a company outright⟦c36⟧. Midi went on to reach a $1 billion valuation after its 2026 Series D round, having grown largely inside partner distribution channels instead of under new ownership⟦c37⟧⟦c38⟧. A partnership can build a company's value to the point where an acquisition becomes prohibitively expensive, or where the startup simply has the leverage to pick its own exit rather than accept someone else's terms. Health systems appear to be using these partnerships as a low-cost way to road-test femtech operators before they ever put acquisition capital on the table, and the companies that perform well inside those partnerships are, unsurprisingly, the ones whose valuations keep climbing.

What capabilities health systems are buying, category by category

Look across the confirmed deals and the partnerships together, and four capability clusters stand out as the actual targets⟦c39⟧.

Menopause and midlife care is the most financially validated of the four ⟦c39⟧. KaNDy's $425 million exit to Bayer, Midi Health's $1 billion valuation, and Hinge Health's decision to partner with Midi for menopause coverage all point the same direction⟦c40⟧. Menopause went underserved clinically for decades, and what's changing hands now isn't just a drug or an app, it's the clinical protocol, the prescribing infrastructure, and the patient trust that legacy providers never built⟦c18⟧. Midi Health raised $100 million in its 2026 Series D and remains independent, which makes it one of the more closely watched potential targets left standing⟦c41⟧.

Fertility and reproductive health infrastructure is the second cluster, and it's shifting from standalone clinics toward benefits administration. Progyny's purchase of Apryl GmbH for European reach, Maven's acquisition of Naytal, and Kin's inclusion inside the Eucalyptus portfolio all point at the same underlying shift: fertility benefits have become a product employers and payers buy at scale, and acquirers want the whole delivery and administration stack, not a single IVF clinic bolted onto an existing network⟦c42⟧⟦c43⟧. Kindbody sits just outside this pattern in an instructive way. With $290 million in total funding and a $1.8 billion valuation, it's reportedly eyeing a 2027 IPO instead of a sale, which is a reminder that not every strong femtech company ends up inside a health system's balance sheet⟦c44⟧.

Maternal mortality and morbidity rates in the U.S. are a documented crisis, and the liability and reputational risk this creates drives acquisition urgency for health systems that want to close care gaps in this area⟦c46⟧. Diana Health's embed inside HCA is the sharpest real-world example of a system trying to close that gap without waiting for a slow internal build⟦c47⟧.

The fourth cluster is broader: full-stack virtual care platforms that don't specialize in one condition but follow a patient across her whole reproductive life. Eucalyptus is the cleanest example, a platform spanning multiple conditions and multiple countries under one direct-to-consumer clinical model⟦c48⟧. Maven Clinic makes the same point at even larger scale, with 17.5 million covered lives, 550 menopause clients, and a pediatrics product covering 3 million more lives⟦c49⟧. The value in a platform like that was always the longitudinal relationship, not any single condition. It's the longitudinal relationship: Maven Clinic, with 17.5 million covered lives, 550 menopause clients, and a pediatrics product covering 3 million lives, illustrates that the value is not any single condition but the longitudinal patient relationship across reproductive life stages⟦c49⟧. Landbase reports that Iron Health, offering virtual primary care, behavioral health, and pregnancy care, was acquired by Metronomic in December 2024, while Pomelo Care, valued at $1.7 billion, raised $92 million in 2026 as it expanded beyond maternity ⟦c45⟧.

The companies most likely to be acquired next

The strongest acquisition candidates left on the board share a proven clinical model, a large base of covered lives or patients, and existing distribution through employers or payers ⟦c61⟧. Consumer apps alone don't make that list.

Maven Clinic tops it by scale ⟦c13⟧. Its 17.5 million covered lives make it the largest fertility benefits administrator anywhere, its pediatrics product covers 3 million lives, and its menopause offering has grown to 550 clients⟦c50⟧⟦c51⟧. Amazon reportedly replaced Progyny with Maven as its primary fertility benefits provider, and that kind of enterprise-level validation is precisely what a health system chasing employer-channel access would want to buy⟦c52⟧. Maven may simply be too large and too expensive for most health systems to absorb, which makes a large insurer or benefits platform a more plausible buyer than a hospital network⟦c53⟧.

Midi Health is the second name on the list, carrying a $1 billion valuation after its 2026 Series D, with $100 million of that round led by Goodwater Capital⟦c54⟧⟦c55⟧. Its focus stays tight on menopause and midlife care, and it's already proven it can operate inside a partner's distribution network through the Hinge Health relationship, which gives any prospective acquirer a clear, tested picture of what the synergies would look like⟦c56⟧.

Pomelo Care rounds out the list, valued at $1.7 billion after a $92 million Series C in January 2026 led by Stripes, and it's already pushing beyond maternity into adjacent conditions⟦c57⟧⟦c58⟧. Maternal care carries the most acute, most publicly documented outcomes crisis of any category in this piece, and the regulatory and payer pressure on health systems to fix it isn't easing up. Pomelo's model sits directly in the path of that pressure, which is exactly why it belongs on any list of likely next targets⟦c59⟧.